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In the present study, we have investigated insulin-
like growth factors (IGFs) and their binding proteins 
(lGFBPs) in serum and artificially raised blister fluid 
from uninvolved and involved areas of nine patients 
with psoriasis. Both levels of IGFs and IGFBP-3, and 
profiles of IGFBP ill. serum and fluid from the unin-
volved areas of these patients were comparable to 
those seen in normal subjects. Ill. fluid from the 
involved areas, the IGF-II but not IGF-I level was 
significantly elevated. Among five molecular forms 
ofIGFBP, the density of 41.5- and 38.5-kDa forms of 
IGFBP-3 were apparently increased ill. fluid from the 
involved areas, shown by Western ligand blotting. 
Radioimmunoassay further showed that the IGFBP-3 
concentration in the involved areas was significantly 
I n serum and other body fluids, insu lin-like growth f.,ctors (IGF-I and IGF-lI) are known to be bound to their binding proteins (IGFBPs). Six IGFBPs have so f.,r been identified and referred to as IGFBP- l through IGFBP-6. They mod-ulate the access of IGFs to their receptors and may function 
in either a stimulatory or an inhibitory manner [1]. This modu lation 
is further complicated by specific proteases such as IGFBP-3 
protease, which has been found in the serum under certain condi-
tions [2-5] and in some extra-circulation body fluids such as lymph, 
cerebrospinal fluid, amniotic fluid, urine , and seminal plasma [6-8]. 
Tlus enzyme is postulated to reduce the affinity of IGFBP-3 for 
IGFs and therefore render the IGFs more readily availabJe to tissues 
[2,3]. 
Expression of IGF-I transcripts and peptides has been shown in 
human skin fibrobl as ts and melanocytes [9], and in Langerhans cells 
[10], respectively. Skin keratinocytes appear not to produce IGF-I 
but possess IGF-I receptors [9] and produce IGFBPs as do skin 
fibroblasts [11,12]. In addition, the IGFs, various IGFBPs and 
IGFBP-3 protease have been demonstrated in skin interstitial fluid 
[13]. 
The pathogenesis of psoriasis currently is not clear, but overex-
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raised. Immunoblotting revealed that the predomi-
nant form of IGFBP-3 ill. fluid from the uninvolved 
areas was a 29-kDa proteolytically modified product. 
In contrast, intact doublet IGFBP-3 was the main 
form of IGFBP-3 in fluid from the involved areas. 
Fluid from the involved areas but not the matched 
serum concentration-dependently inhibited the deg-
radation of 125I_Iabeled nonglycosylated IGFBP-3 
(ngIGFBP-3) caused by fluid from the uninvolved 
areas, suggesting the presence of an IGFBP-3 pro-
tease inhibitor(s) in psoriatic skin lesion. These find-
ings suggest that the alterations in IGF/IGFBP system 
may contribute to the pathogenesis of psoriasis. Key 
words: suction blister flllidiproteolysislpl'otease inhibitor, 
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pression of growth factors, cytokines, or their receptors, such as 
transforming growth factor-a (TGF-a), interleukin- 6 (IL-6), epi-
dermal growth factor (EGF) receptors, and IGF-I receptors, have 
been shown in psoriatic skin and are believed to contribute to 
keratinocyte hyperproliferation [14,15].' In the present study we 
have investigated a possible ro le for IGF/ IGFBP system in the 
pathogenesis of psoriasis by analyzing IGFs, IGFBPs, and IGFBP-3 
protease activity in artificially raised blister fluid £i'om psoriatic 
patients and demonstrated the presence of an TGFBP-3 protease 
inhibitor(s) and the increase in the levels ofIGF-II and IGFBP-3 in 
the psoriatic lesion. 
MATERIALS AND METHODS 
Materials IGF-I monoclonal antibody and so lid phase anti-mouse and 
anti-rabbit antibodies (Sac-CeI) were obtained from Dlood Products Ltd . 
(Hertfordshire . UK) and rDS (Tyne and Wear. UK) , respectively. IGFBP-3 
polyclonal antibody (SCH 2/5) against nonglycosylatcd IGFBP-3 (ngIG-
FBP-3) was raised in our laboratory [1 6]. TGF- IT monoclonal antibody. 
recombinant human IGF-I and TGF-n. and recombinant human nonglyco-
sylated and glycosylated lGFDP-3 were kindly provided by Dr. Anll White 
(University of Manchester. UK). Kabi Pharmacia (Stockholm, Sweden). 
and Dr. C. A. Maack in Celtrix Pharmaceuticals (Santa C lara, CAl, 
respectively . Unless otherwise stated. all other reagedts were purchased 
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from Sigma (Dorset, UK). IGF-I and - II , and IGFI3 I'-3 were iodinated using 
the chloram ine-T method. 
Samples Nine patients (six males and th ree fe males: agc range 32- 66 y 
with a mean of 49 y) with plaque-type pso ri asis (two growing. five stable. 
and two regress ing ) unde l- vario us t rcatlllents. su ch as retino id, .PUVA, and 
vitami n D" volun tarily participated in tlus study. T he IGF levels, IGP131' 
I rofiles . '\I~d IGFI3P-3 protease activities did not appear to difFer according 
to the condition of plaques or to the treatment received by the pa tients. 
In fo rmed consent was obt,d ncd fro m the subjects, 'lI1 d the study was 
approvcd by the ethics commi ttee of the Uni ted n ri sto l H ealthGlre T rust. 
Bliste rs were raised by application or a negative pressure of 200 mm I-I g to 
the skin fo r 1-2 h as described \.1 71. Approx imately 1.5 ml of blister Auid 
,·vas obta ined fi·ol11 each suction and serUn1 s:lInp lcs \.ycrc taken Silll ul ta-
ncously. Samples were stored at - 20°C un til usc. Haemoglobin in blister 
fluid was determined . A normal serum pool from young hea ldlY adul t 
vo luntee rs and a SCrlllTI poo l fi·Oll l no rnla i "VOll l e n in th e thi rd t rilll cstc r or 
pregna ncy were used as reference m<lteri als. 
Western Ligand Blotting Western liga nd blotting was perfo rmed as 
described ['I 8J. Autorad iographs of blots were scann ed wi th <In UltroScan 
XL lase r densitometer (Pharmac ia U(13 . Bromma. Sweden) , and the 
integra ted areas under th e abso rbance curves we re expressed in arbitrary 
uni ts (AU). 
Im m u noblotting Nitrocc Uulose membranes, re-used after ·Westc rn li-
gand blotting. were blocked with a buffe r conta ining 10 InM Tris HCI, 150 
111 M NaCI. 5'10, f.1t-frce dried mil k. and 0.2% Twecn-20 (pH 7.4) for 6 - 8 h. 
and then incubated with a specifi c polycIonal anti- IGFI3P-3 antibody SCH 
2/5 (I :4000 fina l dilution) overn ight at room temperature . Aftcr thorough 
washi ng in the buff'er. the mcmbranes Were incubated fo r 1 h with " 
horseradish peroxidase-conjugated anti-rab bi t IgG 'Illtibody (1 :10000 fin al 
dilu tion) and the bands visua lized by chemiluminescence with an ECL 
detection sys tem (A mcrsham In t., Buckinghamshire, UK). 
Measurem ent of P rotease Activity IGF13P-3 pro tease acti vity was 
measured as previously described rI 9]. 
R adio im nuJl1oassays Radioimmunoassays (R.IA s) for IGFs and 
IGFBP-3 we re " "rformed as previously described P 6,20·' . 
P rotein Assay Tota l prote in levels in serul11 and bliste r Auid samples 
were measured using the Prote in Assay Kir 23200 (Pierce, Chester. UK). 
Statistical An alysis Data arc presented '15 mean ::': SD and compari sons 
were ana lyzed using StlIdent's paired t test. with significance defin ed as p < 
0.05. 
llES ULTS 
Measu rements of I GF Levels T he IGF-I and IGF-II concen-
trations in serum fi:o m nine patien ts were 138 ± 19 and 580 ± 51 
/-I,g/l , respective ly. T h e ICF-Ilevel in blister Auid fi'olll the involved 
areas w as simil al' to tha t from th e unin volv ed areas (26 ± 8 I'S 25 ::!:: 
9 f,Lg/ l) bu t th e IGF- II le ve l w as signifI cantly e le vated in th e 
in volved areas (167 ::!:: 33 lIS 93 ::!:: 18 f,Lg/ I: p < 0.01) (F ig la). A fter 
no rmali zatio n fo r the p ro te in co n cen tratio n in bli ste r Auid , an 
in crease in the IGF-II level was still fo und in t he involved areas 
(9 ::!:: .I lIS 6 ::!:: 1 /.Lg/g pro tein : p < 0 .05) (Fig 1/J). 
C omparison o f I G F BP Profiles b e tween F luids from the 
Uninvolved a nd I n v olved Areas IGFB Ps in serum and bliste r 
Auid sa m ples were ana lyzed by Western liga nd blo ttin g. All the 
serum sampl es fi'om the patien ts sh owed similar IGFBP profile to 
the no rma l serum (daw no t shown) . In bli ste r Auid ta ken from 
e ithe r uninvo lved o r in volved areas of psori as is, fi ve m olecul ar 
fo rm s o f {GFB P (4 '1. 5. 38 .5, 3 '1. 28, and 24 kDa) were present. 
T hey ran at the sam e position s as th e tw o glyco sylated fo rms o f 
IGFllP-3, IGFB P-2, - I , and - 4 in no rmal hum an serum , respec-
ti vely. Fig 2a slt ows tlt e ICFBP pro fil es o f th e Auid taken from fi ve 
patients in w hich sa mples were loa ded at eq ual am o un ts of total 
protein. U n der tltis conditi on , the in ten sity of th e 31-, 28-, and 
24-kDa rGFBP bands in fluid fro m the unin volved and m atched 
in volved areas were comparabl e (a rbi tra ry uni ts IAU]) : (J .6 ::!:: 0. 2 liS 
0.7 ± n .2, 1 .4 ::!:: 0.5 lIS 1. 5 ::!:: 0.4, and 0.5 ± 0. 2 I'S 0.5 ::!:: 0.2 , 
respective ly, a ll p > 0.05), w h ile the 41. 5- and 38.5- kDa fo rms of 
IGFBP-3 we re m ore in tense in Auid fro m the in volved areas th an 
those in Auid fro l11 th e unin volved areas (AU: 19 ::!:: 3 /IS 8 ::!:: 2, P < 
(J.01). Measured b y RJA, th e m ean concen trati o ns of JGFBP-3 in 
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Figure 1. Elevated IGF-ll level in blister fluid from the involved 
areas. IGF-I and IGF-II levels in the blister Auid from nine patients with 
psoriasis were measured by R..IA using IGF- I or -II monoclonal antibodies. 
Em". IWI"s, SD. "p < 0.05; " 1' < 0.0 I (pa ired t test). 
th e inv o lved and unin volved areas w ere 1 .9 ::!:: 0 .3 mg/ l and 1.3 ± 
0.3 rn g/ l, respecti vely. Normalized 0 11 the basis o f to tal protein 
concentration , th e IGFBP-3 le vel in Auid fi 'orn the invol ved areas 
was 1.2-fo ld o f that li ol11 th e uninvolved areas (105 ::':: 6 /IS 85 ::':: 6 
f,Lg/g pro te in: p < 0.05). 
Reduced IGFBP-3 Protease Activity in Fluid from the 
Involved Area T he presen ce of a high level o fl GFBP-3 pro tease 
activi ty has been o bserved in n o rmal skin in te rsti t ia l Auid [1 3] . To 
exa min e if this acti vi ty was alte red in th e in volved a reas and 
the refo re accoun ted fo r th e intensifi ed IG FBP-3 bands as sho wn in 
F ig 2a , th e m embrane was subsequentl y iml11unoblo tted (Fig 21/). 
In addi tio n to the inta ct d o uble t IG FBP-3, a 29-kDa band was 
d e tected. T hi s band was a fra gm en t ra the r than the n on glycosylated 
fo rm of IGFBP-3 as it was no t de tected by W este rn ligand blotting, 
w hich co uld reveal th e latter fo rm since it re tains ligand bindin g. In 
Auid from th e uninvol ved areas, 68 ::!:: 8'1., o f IG FBP-3 was in 
29-kDa fo rm , while in Auid fro m th e invo lved areas o nly 38 ::!:: 6% 
be lon ged to this £i'agm ent (I' < 0 .005) . T h e amounts o f 29- kDa 
IGFBP-3, howe ver , were n o t signifi cantl y diffe rent b e tween Auids 
fro m uninvolved and in vo lved are as. T hus, the m aj o r diffe rence Jay 
in t he am o unt o f in tact fo rm . 
IGFllP- 3 protease activ ity was m easured to confirm the differ-
ence be tween uninvolved and in volved areas. Samples £i'om the 
sa l11 e fi ve patients w ere incubated with 125 1_l abe led 30-kDa ng lG-
FBp-3. Incuba tio n w ith Auid £i'om th e uninvo lved areas res ulted in 
an apparent degradation of the intac t n g ICFBP-3 into fra gments of 
15 and 21 kDa, and the remainin g intac t form was 33 ::!:: 7"/., o f the 
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Figure 2. Altered IGFBP-3 profile in blister flu id from the involved 
areas. Blister fluid from five patients with psoriasis were loaded at eq ual 
amounts of total protein. a) Western Ligand blot probed with a mix ture of 
1251_IGF_1 and -IGF-II. /I) IGFBP-3 immunoblot detected by anti-IGFBp-3 
polydonal antibody SCH 215. L,,"" 1. normal serum pool (NS) as contro l; 
lalles 2. 4. 6, 8. and Hi. blister fluid fl"Om the uninvolved areas (ll); lalles 3, 
5, 7, 9, and II. blister fluid fi'om the matched involved areas (I). 
control value (as estimated by densitomett·y). The extent of such 
degradation was significantly reduced when the n g IGFBP-3 was 
incubated with matched fluid from the in volved a reas and the 
remaining intact form in creased to 81 :': 11
'
;1., of the control value 
(Fig 3). In two subjects (Fig 3, L(lI1es 10 and 14) , the proteolytic 
activity was almost neg ligible. 
Presence ofIGFBP-3 Protease Inhibitor(s) in Fluid from the 
Involved Area To investigate if the reduced IGFBP-3 protease 
activity in fluid from the involved areas of psoriasis was due to a 
lack of this en zym e or an inhibition of the proteolytic activity, the 
fl uid frOI1l the uninvolved area at a fixed con centration was 
coin cubated with graded concentrations of the fluid fi'om the 
involved area or serum fi'om the sam e patient. As shown in Fig 4, 
serum at all concentrations failed to block the degradation of 
12sI_labe led n gIGFBP- 3 caused by fluid fi'ol11 the uninvolved area. 
Interes tingly, fluid from the involved area inhibited this lGFBP-3 
proteolytic activity in a dose-dependent l11anner. 
DLSCUSSION 
In the present study, we have examined IGF/ IGFBP in skin 
interstitial fluid take n liOln the uninvolved and involved areas of 
the patients with psoriasis. The leve ls of IGFs, IGF13Ps, and 
IGFBP-3 proteo lytic activity in the serum and b lister fluid from the 
uninvolved areas did not differ signifi ca ntly fi'om those in norl11al 
subjects 1.13]. The IGF-I leve l in fluid from the involved areas was 
also in the 1I0rmal range . This appears in agreement with a previous 
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Figure 3. Proteolytic degradation of IGFBP-3 by blister fluid. 
125 r-ngIGFBP-3 was incuba ted ilt 37°C for 24 h with the hliste r Auid &om 
the uninvolved or involved areas of fivc paticnts with psoriasis. La/ll' 1. 
12' I_ngIGFI3P-3; Inlle 2. normal serum pool (NS); lallI' 3. third trimester 
pregnancy serum (P5); lalli' 4, PS + 60 111M ethylenediamine tctraacetic 
acid; lalles 5. 7,9. 11. and 13 . blister Auid from the uninvolved areas (ll); 
lalles 6. 8. 10, 12, and 14. blister fluid from the matched involved areas (.1). 
finding that IGF-I trallScripts are not overexpressed in psonatlc 
lesions [21 ]. III contra st to IGF- I , IGF-IT was found to be signifi-
cantly raised in the lesional skin. Since !GF-I1 is known to act on 
IGF-I receptors as a potent mitogen (though n ot as potent as IGF-I) 
for many cell types including skin keratinocytes [22] , the e levated 
rGF-I1 level found he re may indi cate a potentially important role 
for it in the hyperproliferation of psoriatic les ions. T his suggestion 
correlates well with th e t1nding that IGF-I receptors arc overex-
pressed in the psoriatic les io nal skin . I As activation of IGF-I 
receptors is capa bl e of tran s1110dulating EGF receptors on keratino-
cytes [23 ], the elevated I G.F-ll might also contribu te to '1Il increase 
in express ion of EGF receptors in psoriasis [15]. 
Western ligand blotting showed that IGFBP- 3 but no t othe r 
IGFBPs increased in fluid fi'om the invo lved areas, which was du e 
to both e levated IGFBP- 3 level and decreased IGFBP-3 proteolytic 
activity. The e levated IGF13P- 3 might be the consequen ce of the 
in creased IGF-I1 , as IGF-I has been shown to be able to induce 
d issociation of m e mbrane-associated intact IGFBP-3 124J. Or con-
versely , sin ce IGFBPs determine the level of lGF th at can be 
maintained, th e highe r IGF-U con centratio n may be due to an 
increase in levels and stab ility of IGFBP-3. 
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Figure 4. Inhibition of IGFBP-3 proteolytic activity by fluid frOI11 
the involved area. 125 1_ngIGF13I'_3 was incubated :It 37°C for 2-l h with 
blister fluid from the uninvolved arca (ll) in combination with graded 
concentrati on of either serul11 (5) or blister Huid ~i'ol11 the in volved area (I) 
of the same patiellt. Lnlll' I, 11'I-ngIGFBP-3; lalli' 2. U + 60 mM 
ethylenediamine tetraacetic acid; lalle 3. U alone; lalli'S .J through 6. U + 
difrcrellt amount of serum (5 I , 52, and 53) whose total protein level were 
equal to ll, 12. and 13 , respectivel y; lalit'S 7 through 9. U + 25.37.5 . and 50 
f.LI of I (I I. 12. and IJ). respective ly. All the samples were adjusted with 
phosphate buR'er to equal total volume before incubation. 
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Modification ofIGFBP-3 by specific proteases is hypothesized to 
enable IGF to be more readily released frol11 IGFBP-3 and therefore 
to control IGF access to target tissues. T he role for intact IGFBP-3 
itself in mediating IGF actions at the cellular level, however, 
remains uncl ear. Both inhibitory and stimulatory effects have been 
reported [25-27]. The former is postu lated to be mediated by 
soluble IGFBP-3 , which might sequester IGF-I and thus prevent 
interaction with its receptor. The mechanism for the potentiation 
effect is even more obscure. Possible explanations are that the 
enhan cem ent ofIGF-I action by IGFBP-3 might be associated with 
targeting the action ofIGF-I via IGFBP-3 cell association, protect-
ing IGF-I from degradation by proteases or inhibiting fGF-I-
induced receptor downregulation and cellular desensitization 
[27,28]. In blister Auid both from normal subjects [13] and from the 
uninvolved areas of patients with psoriasis (this report), high levels 
of IGFBP-3 proteolysis have been found. In contrast, this proteo-
lytic activity was diminished in Auid from the hyperproliferative 
psoriatic lesions. Thus, it is possible that intact rather than fi·ag-
men ted IGFBP-3 may playa role in en hancing the mitogenic action 
ofIGFs in the pathogenesis of psoriasis . Such a stimulatory efFect of 
fGFBP-3 has been seen in skin fibroblasts, where IGFBP-3 is 
supposed to keep a continuous IGF-I supply (26). This hypothesis, 
of co urse, remains to be exam.ined directly in human skin kerati-
nocytes. 
The reduced proteolytic activity of IGFBP-3 in psoriatic lesions 
was found to have resulted frOI11 the presence of an inhibitor(s) for 
IGFBP-3 protease, as demonstrated by coincubation of blister Auid 
fi:ol11 the uninvolved and involved areas . Lack of such inhibitor(s) 
in the matched serum indicated that it was produced locally in the 
involved skin . From this finding, we hypothesize a role for 
IGFBP-3 protease inhibitor(s) in cell proliferation under patholog-
ical conditions such as pSOl;asis. The property and source of tills 
inhibitor(s) are obviously worth further inves tigatio n. 
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